Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension

Fig. 2

Efficacy results from Period I (double-blind study) from weeks 0 to 24 for a ACR20 response rate, b ACR50 response rate, c ACR70 response rate, d ACR20, ACR50, and ACR70 response rates at week 24, e mean DAS28-CRP (95% CI) from weeks 0 to 24. ACR American College of Rheumatology, CI confidence interval, DAS28-CRP disease activity score 28 based on C-reactive protein, RP reference product

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us